NASDAQ:VNDA

Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
····

Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data

Vanda Pharmaceuticals shares fell 0.5% to $6.15 in premarket trading Thursday, trimming part of Wednesday’s 3.2% gain. First-quarter net product sales rose 3% to $51.7 million, but the company posted a $48.6 million net loss and used $50.2 million in operating cash. Vanda raised 2026 revenue guidance to $240–$290 million, expecting Nereus to contribute up to $30 million this year.
May 21, 2026

Stock Market Today

  • ASX Mid-Cap Shares Poised for Growth as Market Shifts from Mega-Caps: VanEck Report
    May 29, 2026, 9:14 PM EDT. A VanEck report highlights that ASX mid-cap shares, historically overshadowed by large caps like BHP and Commonwealth Bank, are gaining investor interest. With bond yields at multi-decade highs and large-cap earnings under pressure, mid-caps trading at discounts to the ASX 50 now attract attention for potential earnings growth. VanEck notes that during periods of higher interest rates and slower growth, broader market leadership emerges as investors seek reliable earnings growth beyond mega-caps. Signs of this shift appear in both the U.S. and Australia, where smaller companies have delivered strong earnings surprises post-February reporting. Mid-caps' cheaper valuations amid improving earnings outlooks suggest these stocks may play a bigger role amid inflation, rising bond yields, and geopolitical risks.